← Browse by Condition
Medical Condition

tenosynovial giant cell tumor

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 4

ClinicalMetric tracks all active clinical trials for tenosynovial giant cell tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — tenosynovial giant cell tumor Clinical Trials

How many clinical trials are currently recruiting for tenosynovial giant cell tumor?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for tenosynovial giant cell tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for tenosynovial giant cell tumor?
tenosynovial giant cell tumor research spans Phase 1 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a tenosynovial giant cell tumor clinical trial?
Eligibility criteria for tenosynovial giant cell tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 4
1
Top Sponsors
Abbisko Therapeutics Co, Ltd 1 trial
Daiichi Sankyo 1 trial
Shanghai Jiao Tong University Affiliated Sixth People's Hospital 1 trial

Recruiting Clinical Trials

NCT04192344 Phase 1
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Enrollment
276 pts
Location
United States, China
Sponsor
Abbisko Therapeutics Co, Ltd
View Trial →
NCT04635111
Recruiting
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Enrollment
30 pts
Location
United States
Sponsor
Daiichi Sankyo
View Trial →
NCT07315841 Phase 4
Recruiting
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
Enrollment
40 pts
Location
China
Sponsor
Shanghai Jiao Tong University ...
View Trial →

Related Conditions

neoplasms (1) hepatotoxicity (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology